What is HC Wainwright’s Forecast for PTGX FY2024 Earnings?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities research analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Protagonist Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $1.82 for the year, up from their previous forecast of $1.44. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.33 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.61) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.53) EPS, FY2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.55) EPS and FY2027 earnings at ($0.41) EPS.

PTGX has been the subject of several other research reports. JMP Securities lowered their price target on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a report on Wednesday, August 7th. Wedbush reaffirmed an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Monday, November 4th. StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. BTIG Research upped their target price on Protagonist Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Finally, Truist Financial started coverage on Protagonist Therapeutics in a report on Monday, September 9th. They issued a “buy” rating and a $60.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $53.57.

Protagonist Therapeutics Trading Down 3.8 %

Shares of PTGX stock opened at $41.04 on Thursday. The stock has a 50-day moving average of $45.66 and a 200-day moving average of $38.49. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of 15.86 and a beta of 2.17. Protagonist Therapeutics has a 1-year low of $15.58 and a 1-year high of $48.89.

Insiders Place Their Bets

In other Protagonist Therapeutics news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director now owns 12,000 shares in the company, valued at approximately $540,000. This represents a 40.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the transaction, the chief financial officer now owns 34,960 shares of the company’s stock, valued at $1,555,370.40. This represents a 28.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.40% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of PTGX. Sei Investments Co. boosted its holdings in Protagonist Therapeutics by 12.2% during the 1st quarter. Sei Investments Co. now owns 41,758 shares of the company’s stock worth $1,208,000 after acquiring an additional 4,529 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Protagonist Therapeutics in the 1st quarter worth approximately $35,000. ProShare Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 9.2% in the first quarter. ProShare Advisors LLC now owns 14,345 shares of the company’s stock valued at $415,000 after acquiring an additional 1,206 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Protagonist Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock valued at $92,373,000 after acquiring an additional 39,055 shares in the last quarter. Finally, Seven Eight Capital LP bought a new stake in Protagonist Therapeutics during the first quarter worth $202,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.